Comparative Pharmacology
Head-to-head clinical analysis: ESTROSTEP 21 versus KARIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROSTEP 21 versus KARIVA.
ESTROSTEP 21 vs KARIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Terminal elimination half-life is 4.5 hours; in renal impairment (CrCl <30 mL/min), half-life may extend to 8-10 hours, requiring dose adjustment.
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Approximately 55% renal (30% as unchanged drug, 25% as metabolites) and 45% fecal (via biliary elimination).
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive